496 | Humans |
325 | Male |
281 | Female |
258 | Parkinson Disease |
246 | Middle Aged |
202 | Aged |
152 | Adult |
86 | Antiparkinson Agents |
76 | Levodopa |
75 | Severity of Illness Index |
62 | Magnetic Resonance Imaging |
55 | Animals |
54 | Deep Brain Stimulation |
50 | Treatment Outcome |
49 | Brain |
45 | Neuropsychological Tests |
44 | Subthalamic Nucleus |
44 | Neurologic Examination |
43 | Dystonia |
42 | Aged, 80 and over |
41 | Electromyography |
36 | Adolescent |
35 | Movement Disorders |
35 | Follow-Up Studies |
34 | Dose-Response Relationship, Drug |
31 | Questionnaires |
31 | Parkinsonian Disorders |
31 | Globus Pallidus |
31 | Double-Blind Method |
29 | Electric Stimulation Therapy |
29 | Dyskinesia, Drug-Induced |
28 | Tremor |
26 | Time Factors |
26 | Diagnosis, Differential |
26 | Cognition Disorders |
26 | Chorea |
25 | Young Adult |
24 | Functional Laterality |
24 | France |
24 | Electrodes, Implanted |
24 | Corpus Striatum |
23 | Multiple System Atrophy |
23 | Drug Therapy, Combination |
23 | Disability Evaluation |
22 | Reproducibility of Results |
22 | Mutation |
21 | Thalamus |
21 | Dopamine |
20 | Neurons |
20 | Myoclonus |
20 | Cerebral Cortex |
20 | Case-Control Studies |
20 | Brain Mapping |
19 | Retrospective Studies |
19 | Parkinson Disease, Secondary |
19 | Dopamine Agonists |
19 | Analysis of Variance |
18 | Substantia Nigra |
18 | Dominance, Cerebral |
18 | Child |
17 | Psychiatric Status Rating Scales |
17 | Drug Administration Schedule |
17 | Disease Progression |
17 | Age of Onset |
16 | Posture |
16 | Electric Stimulation |
16 | Dystonic Disorders |
16 | Disease Models, Animal |
15 | Psychometrics |
15 | Motor Activity |
15 | DNA Mutational Analysis |
14 | Reaction Time |
14 | Prospective Studies |
14 | Indoles |
14 | Huntington Disease |
14 | Genotype |
14 | Depression |
14 | Dementia |
13 | Statistics, Nonparametric |
13 | Quality of Life |
13 | Neural Pathways |
13 | Gait Disorders, Neurologic |
13 | Basal Ganglia |
13 | Basal Ganglia Diseases |
12 | Stereotaxic Techniques |
12 | Prevalence |
12 | Image Processing, Computer-Assisted |
12 | Child, Preschool |
12 | Activities of Daily Living |
11 | Tomography, Emission-Computed, Single-Photon |
11 | Polysomnography |
11 | Nerve Tissue Proteins |
11 | Muscle, Skeletal |
11 | Dopamine Agents |
11 | Bromocriptine |
11 | Apomorphine |
11 | Age Factors |
10 | Psychomotor Performance |
10 | Phenotype |
10 | Neurodegenerative Diseases |
10 | Longitudinal Studies |
10 | Family Health |
10 | Electroencephalography |
10 | Dyskinesias |
10 | Cross-Sectional Studies |
9 | Transcranial Magnetic Stimulation |
9 | Tomography, X-Ray Computed |
9 | Tomography, Emission-Computed |
9 | Supranuclear Palsy, Progressive |
9 | Risk Factors |
9 | Reference Values |
9 | Rats |
9 | Postural Balance |
9 | Nerve Degeneration |
9 | Motor Cortex |
9 | History, 20th Century |
9 | Europe |
9 | Combined Modality Therapy |
9 | Cerebrovascular Circulation |
8 | Videotape Recording |
8 | Syndrome |
8 | REM Sleep Behavior Disorder |
8 | Positron-Emission Tomography |
8 | Piribedil |
8 | Pedigree |
8 | Muscle Rigidity |
8 | Movement |
8 | Genetic Predisposition to Disease |
8 | Gait |
8 | Frontal Lobe |
8 | Cognition |
8 | Cerebellum |
8 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
7 | alpha-Synuclein |
7 | Ubiquitin-Protein Ligases |
7 | Thalamic Nuclei |
7 | Spinal Cord |
7 | Sensitivity and Specificity |
7 | Restless Legs Syndrome |
7 | Receptors, Dopamine |
7 | Odds Ratio |
7 | Neurosurgical Procedures |
7 | Multiple Sclerosis |
7 | Mice |
7 | Mesencephalon |
7 | Mental Status Schedule |
7 | International Cooperation |
7 | Injections, Intramuscular |
7 | Hand |
7 | Guadeloupe |
7 | Gene Frequency |
7 | Evoked Potentials, Somatosensory |
7 | Essential Tremor |
7 | Cross-Over Studies |
7 | Biomechanical Phenomena |
7 | Benzothiazoles |
7 | Attention |
7 | Atrophy |
6 | Video Recording |
6 | Statistics as Topic |
6 | Spinocerebellar Ataxias |
6 | Radiopharmaceuticals |
6 | Predictive Value of Tests |
6 | Point Mutation |
6 | Pergolide |
6 | Pain |
6 | Pain Measurement |
6 | Nuclear Proteins |
6 | Neuroprotective Agents |
6 | Molecular Chaperones |
6 | Imaging, Three-Dimensional |
6 | Emotions |
6 | Confidence Intervals |
6 | Autonomic Nervous System Diseases |
5 | Walking |
5 | Ventral Thalamic Nuclei |
5 | Tyrosine 3-Monooxygenase |
5 | Torticollis |
5 | Stereotyped Behavior |
5 | Somatosensory Cortex |
5 | Receptors, Dopamine D2 |
5 | Receptors, Dopamine D1 |
5 | Proteins |
5 | Postoperative Care |
5 | Polymorphism, Single Nucleotide |
5 | Piperazines |
5 | Pilot Projects |
5 | Patient Selection |
5 | Neural Inhibition |
5 | Motor Skills |
5 | Indans |
5 | Immunohistochemistry |
5 | Hypotension, Orthostatic |
5 | History, 19th Century |
5 | Haplotypes |
5 | Guidelines as Topic |
5 | Genetic Linkage |
5 | Freezing Reaction, Cataleptic |
5 | Evoked Potentials, Motor |
5 | Epilepsies, Myoclonic |
5 | Diagnostic and Statistical Manual of Mental Disorders |
5 | Depressive Disorder |
5 | Cerebellar Ataxia |
5 | Botulinum Toxins |
5 | Behavior, Animal |
5 | Arm |
5 | Antipsychotic Agents |
5 | Anticonvulsants |
5 | Annonaceae |
5 | Amantadine |
4 | tau Proteins |
4 | Vesicular Transport Proteins |
4 | Tropanes |
4 | Tourette Syndrome |
4 | Terminology as Topic |
4 | Speech Disorders |
4 | Smoking |
4 | Single-Blind Method |
4 | Sensation Disorders |
4 | Selegiline |
4 | Rats, Sprague-Dawley |
4 | Protein-Serine-Threonine Kinases |
4 | Preoperative Care |
4 | Postoperative Complications |
4 | Photic Stimulation |
4 | Pesticides |
4 | Oxidopamine |
4 | Outcome Assessment (Health Care) |
4 | Neurotoxins |
4 | Multivariate Analysis |
4 | Motivation |
4 | Mice, Transgenic |
4 | Mental Disorders |
4 | Membrane Transport Proteins |
4 | Macaca fascicularis |
4 | Logistic Models |
4 | Lewy Body Disease |
4 | Lactones |
4 | Injections, Subcutaneous |
4 | Infant |
4 | Hypokinesia |
4 | Hallucinations |
4 | Genetics, Population |
4 | Fluorodeoxyglucose F18 |
4 | Fatal Outcome |
4 | Exons |
4 | Evaluation Studies as Topic |
4 | Energy Metabolism |
4 | Dopamine Plasma Membrane Transport Proteins |
4 | Dopamine Antagonists |
4 | Databases, Factual |
4 | Clinical Protocols |
4 | Chi-Square Distribution |
4 | Cerebral Infarction |
4 | Callithrix |
4 | Botulinum Toxins, Type A |
4 | Body Mass Index |
4 | Blinking |
4 | Blepharospasm |
4 | Athetosis |
4 | Arousal |
4 | Apraxias |
4 | Apathy |
4 | Anxiety |
3 | Weight Gain |
3 | Trinucleotide Repeat Expansion |
3 | Trihexyphenidyl |
3 | Thiolester Hydrolases |
3 | Thiazoles |
3 | Thalamic Diseases |
3 | Temporal Lobe |
3 | Synaptic Transmission |
3 | Sympathetic Nervous System |
3 | Stereotypic Movement Disorder |
3 | Spasm |
3 | Sleep Disorders |
3 | Sex Factors |
3 | Sarcoglycans |
3 | Risk Assessment |
3 | Regression Analysis |
3 | Reflex |
3 | Reflex, Stretch |
3 | Randomized Controlled Trials as Topic |
3 | ROC Curve |
3 | PubMed |
3 | Psychotic Disorders |
3 | Proprioception |
3 | Problem Solving |
3 | Prefrontal Cortex |
3 | Postoperative Period |
3 | Polymorphism, Genetic |
3 | Polymerase Chain Reaction |
3 | Periodicity |
3 | Pattern Recognition, Visual |
3 | Parietal Lobe |
3 | Pain Threshold |
3 | Pacific Islands |
3 | Observer Variation |
3 | Nocturnal Myoclonus Syndrome |
3 | Neuronal Plasticity |
3 | Nerve Net |
3 | Neck Muscles |
3 | Muscle Contraction |
3 | Motor Neuron Disease |
3 | Mitochondrial Diseases |
3 | Microelectrodes |
3 | Mental Recall |
3 | Memory Disorders |
3 | Membrane Proteins |
3 | Membrane Glycoproteins |
3 | Masticatory Muscles |
3 | Macaca mulatta |
3 | MPTP Poisoning |
3 | Linkage Disequilibrium |
3 | Leg |
3 | Iron |
3 | Imidazoles |
3 | Hypertension |
3 | Hepatolenticular Degeneration |
3 | Hemiplegia |
3 | Heart Rate |
3 | Health Surveys |
3 | Health Status |
3 | Glutamic Acid |
3 | Genetic Association Studies |
3 | Galvanic Skin Response |
3 | Friedreich Ataxia |
3 | Fingers |
3 | Fetal Tissue Transplantation |
3 | Fatty Alcohols |
3 | Facial Expression |
3 | Executive Function |
3 | Epilepsy |
3 | Environmental Exposure |
3 | Electrophysiology |
3 | Electrooculography |
3 | Early Diagnosis |
3 | Drug Tolerance |
3 | Disorders of Excessive Somnolence |
3 | Depressive Disorder, Major |
3 | Delayed-Action Preparations |
3 | Deglutition Disorders |
3 | Decision Making |
3 | DNA |
3 | DNA, Mitochondrial |
3 | Cues |
3 | Comorbidity |
3 | Chromosomes, Human, Pair 9 |
3 | Chromosomes, Human, Pair 14 |
3 | Chromosome Mapping |
3 | Cell Death |
3 | Carrier Proteins |
3 | Carbidopa |
3 | Brain Stem |
3 | Brain Diseases, Metabolic |
3 | Apoptosis |
3 | Antidepressive Agents |
3 | Amino Acid Transport Systems, Neutral |
3 | Alleles |
3 | Affect |
3 | Administration, Oral |
3 | Acoustic Stimulation |
3 | Acetogenins |
3 | Accidental Falls |
2 | gamma-Aminobutyric Acid |
2 | Wrist |
2 | Whipple Disease |
2 | Wheat Germ Agglutinin-Horseradish Peroxidase Conjugate |
2 | Weight-Bearing |
2 | Volition |
2 | Vocabulary |
2 | Visual Perception |
2 | Upper Extremity |
2 | Ubiquitin Thiolesterase |
2 | Trinucleotide Repeats |
2 | Transcription Factors |
2 | Tetrabenazine |
2 | Syphilis |
2 | Synucleins |
2 | Synapses |
2 | Supine Position |
2 | Speech |
2 | Space Perception |
2 | Socioeconomic Factors |
2 | Sleep |
2 | Sleep Stages |
2 | Sleep Disorders, Intrinsic |
2 | Skin Neoplasms |
2 | Signal Transduction |
2 | Sickness Impact Profile |
2 | Shoulder |
2 | Serotonin Receptor Agonists |
2 | Schizophrenia |
2 | Riluzole |
2 | Reward |
2 | Reticular Formation |
2 | Regional Blood Flow |
2 | Recovery of Function |
2 | Receptors, Dopamine D3 |
2 | Pyramidal Tracts |
2 | Proportional Hazards Models |
2 | Propionates |
2 | Primates |
2 | Piracetam |
2 | Piperidines |
2 | Phenanthridines |
2 | Personality |
2 | Peripheral Nervous System Diseases |
2 | Pedunculopontine Tegmental Nucleus |
2 | Patient Care Planning |
2 | Paresthesia |
2 | Paraplegia |
2 | Pallidotomy |
2 | Oxygen |
2 | Orientation |
2 | Organic Chemicals |
2 | Olivopontocerebellar Atrophies |
2 | Ocular Motility Disorders |
2 | Nitro Compounds |
2 | Nitriles |
2 | Neurotransmitter Agents |
2 | Neurons, Afferent |
2 | Neurology |
2 | Neural Conduction |
2 | Nervous System Diseases |
2 | Myoclonic Epilepsies, Progressive |
2 | Myocardium |
2 | Muscles |
2 | Muscle Hypotonia |
2 | Motor Neurons |
2 | Mood Disorders |
2 | Monitoring, Intraoperative |
2 | Models, Statistical |
2 | Mitochondria |
2 | Middle Cerebral Artery |
2 | Microinjections |
2 | Mice, Inbred C57BL |
2 | Meige Syndrome |
2 | Median Nerve |
2 | Magnetic Resonance Spectroscopy |
2 | Lung Diseases |
2 | Lod Score |
2 | Locomotion |
2 | Lisuride |
2 | Linear Models |
2 | Laryngeal Diseases |
2 | Kell Blood-Group System |
2 | Interviews as Topic |
2 | Interneurons |
2 | Infant, Newborn |
2 | Inclusion Bodies |
2 | In Vitro Techniques |
2 | Impulsive Behavior |
2 | Immobilization |
2 | Hyperkinesis |
2 | Homeostasis |
2 | History, 21st Century |
2 | Heterozygote |
2 | Heart |
2 | Heart Valve Diseases |
2 | Health Planning Guidelines |
2 | Head Movements |
2 | Haplorhini |
2 | Handwriting |
2 | Hand Strength |
2 | Glucosylceramidase |
2 | Glucose |
2 | Genome-Wide Association Study |
2 | Genetic Testing |
2 | Genetic Markers |
2 | Genes, Dominant |
2 | Gene Dosage |
2 | Gene Deletion |
2 | Gaucher Disease |
2 | Gastrointestinal Tract |
2 | Gambling |
2 | Fluorine Radioisotopes |
2 | Ferritins |
2 | Fatigue |
2 | Family |
2 | Facial Nerve |
2 | Facial Muscles |
2 | Eyelids |
2 | Extremities |
2 | Excitatory Amino Acid Antagonists |
2 | Evoked Potentials, Visual |
2 | Evidence-Based Medicine |
2 | European Continental Ancestry Group |
2 | Ergolines |
2 | Epilepsy, Frontal Lobe |
2 | Encephalomyelitis |
2 | Educational Status |
2 | Dystonia Musculorum Deformans |
2 | Dysarthria |
2 | Drug Synergism |
2 | Drug Resistance |
2 | Drug Combinations |
2 | Domperidone |
2 | Dilatation, Pathologic |
2 | Dihydroxyphenylalanine |